newsfilter
← Earnings
Earnings Releases·

Aprea Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported cash and cash equivalents of $37.8 million as of September 30, 2026, up from $14.6 million at year-end 2025, with a cash runway extending into Q1 2028.
  • Net loss for the quarter was $4.8 million ($0.09 per share) compared to $3.0 million ($0.47 per share) in the prior year period, driven by a significant increase in weighted-average shares outstanding to 53.7 million from 6.4 million.
  • ACESOT-1051 trial enrollment is projected to reach 6–10 patients per month in Q4 2026, with dose selection for Part 2 expected in H1 2027 and expansion enrollment completion targeted for Q2 2027.
  • The ABOYA-119 Phase 1/2a study for ATRN-119 closed in October 2025 establishing a Recommended Phase 2 Dose of 1,100 mg once daily, with exploration of combination therapies underway.
  • Management anticipates increased R&D expenses for APR-1051 due to trial expansion and additional clinical site activation, while planning to present updated Phase 1 interim results at the EORTC-NCI-AACR Symposium in November 2026.
Company
APREA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology